At 3.2% CAGR, the Middle East & Africa Endothelial Dysfunction Market is Projected to be Worth US$ 75.11 million by 2028, says The Business Market Insights

According to the Business Market Insights’ research, the Middle East & Africa endothelial dysfunction market was valued at US$ 62.11 million in 2022 and is expected to reach US$ 75.11 million by 2028, registering a CAGR of 3.2% from 2022 to 2028. Increasing incidences of cardiovascular diseases and rising incidences of high cholesterol, diabetes and obesity are the critical factors attributed to the Middle East & Africa endothelial dysfunction market expansion.                     

According to the World Health Organization (WHO), cardiovascular diseases (CVDs) are among the leading causes of death worldwide, and ~30 million people experience a stroke each year. CVDs include cerebrovascular disease, coronary heart disease, rheumatic heart disease, and coronary artery disease (CAD). CAD is the most common disease among all cardiovascular diseases, and it is characterized by the accumulation of lipids and immune cells in the subendothelial space of the coronary arteries or atherosclerosis. It involves the inflammatory response of the vascular endothelium. CAD is characterized by ischemia, hypoxia, or necrosis of the myocardium resulting from narrowing, spasm, or obstruction of the coronary artery lumen by atherosclerosis. It has become the leading cause of death worldwide.

According to the World Heart Federation, cardiovascular disease is the primary cause of death in the Middle East & North Africa, accounting for more than a third of all deaths or 1.4 million people annually. Further, CVD deaths have increased by 48% over the past 30 years, which accounted for 40% and 10% of deaths in Oman and Somalia, respectively. In 2021, age-standardized CVD mortality rates in the Middle East & North Africa ranged from 134.2 to 600.2 per 100,000 people.

Therefore, the high prevalence of cardiovascular diseases due to endothelial dysfunction drives the market.

On the contrary, disadvantages associated with the techniques for screening of endothelial dysfunction hurdles the growth of Middle East & Africa endothelial dysfunction market.

Based on cause, the Middle East & Africa endothelial dysfunction market is segmented into hypertension, hypercholesterolaemia, obesity, diabetes, behcet's disease, and others. The hypertension segment held 32.7% share of Middle East & Africa endothelial dysfunction market in 2022, amassing US$ 20.33 million. It is projected to garner US$ 25.29 million by 2028 to expand at 3.7% CAGR during 2022–2028.

Based on test type, the Middle East & Africa endothelial dysfunction market is segmented into invasive test and non-invasive test. The invasive test segment held 74.0% share of Middle East & Africa endothelial dysfunction market in 2022, amassing US$ 45.98 million. It is projected to garner US$ 54.83 million by 2028 to expand at 3.0% CAGR during 2022–2028. The non-invasive test segment is further subsegmented into flow mediated dilatory, peripheral arterial tonometry (PAT), venous occlusion pletismography, circulating markers, and others.

Based on end user, the Middle East & Africa endothelial dysfunction market has been categorized into hospitals, diagnostic centers, clinics, and others.  The hospitals segment held 52.0% share of Middle East & Africa endothelial dysfunction market in 2022, amassing US$ 32.32 million. It is projected to garner US$ 39.86 million by 2028 to expand at 3.6% CAGR during 2022–2028.    

Based on country, the Middle East & Africa endothelial dysfunction market has been categorized into the UAE, Saudi Arabia, South Africa, and the Rest of Middle East & Africa. Our regional analysis states that the Rest of Middle East & Africa captured 27.5% share of Middle East & Africa endothelial dysfunction market in 2022. It was assessed at US$ 17.07 million in 2022 and is likely to hit US$ 19.54 million by 2028, exhibiting a CAGR of 2.3% during 2022–2028.      

Key players operating in the Middle East & Africa endothelial dysfunction are ZOLL Medical Corp, The Polymath Co, Perimed AB, SMART Medical Ltd, and Medizinische Messtechnik GmbH, among others.   

• In April 2023, Perimed has signed an agreement with Lovell Government Services. Lovell’s customers are Federal, State, and Local Governments such as the Department of Veteran Affairs (VA), Defense Logistics Agency, and Department of Defense in the United States. With this agreement, Perimed gains an additional sales channel as Lovell will notify the company of any government contract opportunities within its field of business and bid on Perimed’s behalf.

Contact Us
Phone: +16467917070
Email Id: sales@businessmarketinsights.com